Pharmacologic Consideration of Commonly Used Gastrointestinal Drugs in the Elderly

Gastroenterology Clinics of North America

Volumn 38, Issue 3, 2009, Pages 547-562

  Zarowitz, Barbara J ^a,b  

^a Omnicare Inc   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

Author keywords

Aged; Antinauseants; Drug induced conditions; Gastrointestinal; Laxatives; Medications; Proton pump inhibitors

Indexed keywords

17 METHYLNALTREXONE; ANTIEMETIC AGENT; BENZODIAZEPINE DERIVATIVE; BISMUTH SALICYLATE; CIMETIDINE; DOPAMINE RECEPTOR STIMULATING AGENT; FAMOTIDINE; GASTROINTESTINAL AGENT; HALOPERIDOL; HISTAMINE H2 RECEPTOR ANTAGONIST; HYOSCYAMINE; ISPAGULA; LAXATIVE; LOPERAMIDE; LUBIPROSTONE; MAGNESIUM CITRATE; MAGNESIUM HYDROXIDE; METHYLCELLULOSE; METOCLOPRAMIDE; OCTREOTIDE; PHENYTOIN; POLYCARBOPHIL; PROCHLORPERAZINE; PROTON PUMP INHIBITOR; RANITIDINE; SCOPOLAMINE; SPASMOLYTIC AGENT; THEOPHYLLINE; UNINDEXED DRUG; WARFARIN;

ABDOMINAL CRAMP; ABDOMINAL PAIN; AGED; AGING; BLOATING; CENTRAL NERVOUS SYSTEM DISEASE; CONSTIPATION; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG CHOICE; DRUG DISPOSITION; DRUG ELIMINATION; DRUG METABOLISM; DRUG USE; DYSKINESIA; ELDERLY CARE; EVIDENCE BASED PRACTICE; FLATULENCE; FRAIL ELDERLY; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL SYMPTOM; GERIATRIC PATIENT; HEADACHE; HEALTH CARE FACILITY; HELICOBACTER INFECTION; HUMAN; IMPOTENCE; NAUSEA; PATHOPHYSIOLOGY; PEPTIC ULCER; REVIEW; RISK BENEFIT ANALYSIS; SOMNOLENCE; THROMBOCYTOPENIA; UNITED STATES; VOMITING; WEAKNESS;

AGED; AGING; GASTROINTESTINAL AGENTS; GASTROINTESTINAL DISEASES; HISTAMINE ANTAGONISTS; HUMANS; INTESTINAL ABSORPTION; KIDNEY; PROTON PUMP INHIBITORS;

EID: 68749112694     PISSN: 08898553     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gtc.2009.06.011     Document Type: Review

References (48)

1. Relay health claims data warehouse (2008), Omnicare, Inc., Atlanta (GA)
2. Elliott D.P. Pharmacokinetics and pharmacodynamics in the elderly. In: Schumock G.I., Brundage D.M., Hammond Chessman K., et al. (Eds). Pharmacotherapy self-assessment program, 5th edition. Geriatrics and special populations book of PSAP-V (2005), American College of Clinical Pharmacy, Kansas City (MO) 115-126
3. McLean A.J., and Le Couteur D.G. Aging biology and geriatric clinical pharmacology. Pharmacol Rev 56 (2004) 163-184
4. Lindeman R.D., Tobin J., and Shock N.W. Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc 33 (1985) 278-285
5. Giannelli S.V., Patel K.V., Windham B.G., et al. Magnitude of underascertainment of impaired kidney function in older adults with normal serum creatinine. J Am Geriatr Soc (2007) 816-823
6. Levey A.S., Bosch J.P., Lewis J.B., et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130 (1999) 461-470
7. Cockcroft D.W., and Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 16 (1976) 31-41
8. K/DOQI Clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Kidney disease outcome quality initiative. Am J Kidney Dis 39 (2002) S1-246
9. Hanlon J.T., Aspinall S.L., Semla T.P., et al. Consensus guidelines for oral dosing of primarily renally cleared medications in older adults. J Am Geriatr Soc (2008) EOI:10.1111/j.1532-5415.2008.0298.x
10. Clinical Pharmacology Online (2009), Tampa (FL), Gold Standard, an Elsevier Company. http://www.clinicalpharmacology.com/accessed Accessed March 21, 2009
11. Gastroesophageal reflux disease. Geriatric pharmaceutical care guidelines (2009), Omnicare, Inc., Covington (KY) 423-429
12. Yang Y.X., Lewis J.D., Epstein S., et al. Long-term proton pump inhibitor use and the risk of hip fracture. JAMA 296 (2006) 2947-2953
13. Dial S., Delaney J.A., Barkun A.N., et al. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA 294 (2005) 2989-2995
14. Shi S., and Klotz U. Proton pump inhibitors: an update of their clinical use and pharmacokinetics. Eur J Clin Pharmacol 64 (2008) 935-951
15. Ishizawa Y., Yasui-Furukori N., Takahata T., et al. The effect of aging on the relationship between the cytochrome P450 2C19 genotype and omeprazole pharmacokinetics. Clin Pharmacokinet 44 (2005) 1179-1189
16. Chew M., Mulsant B.H., Pollock B.G., et al. Anticholinergic activity of 107 medications commonly used by older adults. J Am Geriatr Soc 56 (2008) 1333-1341
17. Constipation. Geriatric pharmaceutical care guidelines (2009), Omnicare, Inc., Covington (KY) 257-268
18. Fick D.M., Cooper J.W., Wade W.E., et al. Updating the Beers criteria for potentially inappropriate medication use in older adults. Arch Intern Med 163 (2003) 2716-2724
19. Palliative care, pharmacotherapy. Geriatric pharmaceutical care guidelines (2009), Omnicare, Inc., Covington (KY) 661-675
20. Wagner A.K., Zhang F., Soumerai S.B., et al. Benzodiazepine use and hip fractures in the elderly: who is at greatest risk?. Arch Intern Med 164 (2004) 1567-1572
21. Diarrhea: noninfectious. Geriatric pharmaceutical care guidelines (2009), Omnicare, Inc., Covington (KY) 387-393
22. Curtis L.H., Østbye T., Sendersky V., et al. Inappropriate prescribing for elderly American in a large outpatient population. Arch Intern Med 164 (2004) 1621-1625
23. Johnson J.A., and Bootman L.J. Drug-related morbidity and mortality: a cost-of-illness model. Arch Intern Med 155 (1995) 1949-1956
24. Zhang M., Holman D.J., and Preen D.B. Repeat adverse drug reactions causing hospitalization in older Australians: a population-based longitudinal study 1980-2003. Br J Clin Pharmacol 63 (2006) 163-170
25. Gurwitz J.H., Field T.S., Harrold L.R., et al. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA 289 (2003) 1107-1116
26. Abraham B., and Sellin J.H. Drug-induced diarrhea. Curr Gastroenterol Rep 9 (2007) 365-372
27. Diarrhea: Clostridium difficile-associated. Geriatric pharmaceutical care guidelines (2009), Omnicare, Inc., Covington (KY) p. 373-85
28. Owens R.C. Clostridium difficile-associated disease: an emerging threat to patient safety. Pharmacother 26 (2006) 299-311
29. Bartlett J.G. Narrative review: the new epidemic of Clostridium difficile-associated enteric disease. Ann Intern Med 145 (2006) 758-764
30. Muller-Lissner S. General geriatrics and gastroenterology: constipation and faecal incontinence. Best Pract Res Clin Gastroenterol 16 (2002) 115-133
31. Puszlaszeri M.P., Genta R.M., and Cryer B.L. Drug-induced injury in the gastrointestinal tract: clinical and pathologic considerations. Nat Clin Pract Gastroenterol Hepatol 4 8 (2007) 442-454
32. Chen Y.F., Jobanputra P., Barton P., et al. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. Health Technol Assess 12 (2008) 1-198. Available at: www.hta.ac.uk Accessed March 21, 2009
33. Abraham N.S., El-Serag H.B., Hartman C., et al. Cyclooxygenase-2 selectivity of non-steroidal anti-inflammatory drugs and the risk of myocardial infarction and cerebrovascular accident. Aliment Pharmacol Ther 25 (2007) 913-924
34. Bhatt D.L., Scheiman J., Abraham N.S., et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation 118 (2008) 1894-1909
35. Talley N.J. American gastroenterological association medical position statement: evaluation of dyspepsia. Gastroenterol 129 (2005) 1753-1755
36. Sapoznikov B., Vilkin A., Hershkovici M., et al. Minidose aspirin and gastrointestinal bleeding - a retrospective, case-control study in hospitalized patients. Dig Dis Sci 50 (2005) 1621-1624
37. Talley N.J., Vakil N.B., and Moayyedi P. American gastroenterological association technological review on the evaluation of dyspepsia. Gastroenterol 129 (2005) 1756-1780
38. O'Neill J.L., and Remington T.L. Drug-induced esophageal injuries and dysphagia. Ann Pharmacother 37 (2003) 1675-1684
39. Jaspersen D. Drug-induced oesophageal disorders: pathogenesis incidence, prevention and management. Drug Saf 22 (2000) 237-249
40. Sherman A., and Bini E.J. Pill-induced gastric injury. Am J Gastroenterol 94 (1999) 511-513
41. Kikendall J.W., Friedman A.C., Oyewole M.A., et al. Pill-induced esophageal injury: case reports and review of the medical literature. Dig Dis Sci 28 (1983) 174-182
42. Baley Jr. R.T., Bonavina L., McChesney L., et al. Factors influencing the transit of a gelatin capsule in the esophagus. Drug Intell Clin Pharm 21 (1987) 282-285
43. Gastrointestinal disorders: aging and the gastrointestinal tract. In: Beers M.H., and Berkow R. (Eds). The Merck manual of geriatrics. 3rd edition (2000), Merck Research Laboratories, Whitehouse Station (NJ) 1000-1042
44. McLaren R. Drug-induced liver disease. In: Mueller B.A., Bertch K.E., Dunsworth T.S., et al. (Eds). Pharmacotherapy self-assessment program, 4th edition. Gastroenterology, nutrition - PSAP-IV (2002), American College of Clinical Pharmacy, Kansas City (MO) 139-158
45. Kim J. Drug-induced liver disease. In: Richardson M., Chant C., Cheng J.W.M., Chessman K.H., Hume A.L., Hutchison L.C., et al. (Eds). Pharmacotherapy Self-Assessment Program, 6th edition. Gastroenterology and nutrition - PSAP-VI (2009), American College of Clinical Pharmacy, Lenexa (KS) 25-40
46. Larson A.M. Acetaminophen hepatotoxicity. Clin Liver Dis 11 (2007) 525-548
47. Tune L.E. Anticholinergic effects of medication in elderly patients. J Clin Psychiatry 62 Suppl 21 (2001) 11-14
48. Medications with the potential for significant anticholinergic symptoms. Geriatric pharmaceutical care guidelines (2009), Omnicare, Inc., Covington (KY) p. 1033-34